AFP、β-HCG、UE_(3)联合检验在孕中期产前出生缺陷筛查中的应用价值  

AFP、β-HCG、uE_(3) testing in second trimester prenatal birth defect screening

作　　者：李雪燕 陈素丽 姚红霞 LiXueyan;Chen Suli;Yao Hongxia(Department of laboratory medicine,Changji people's Hospital,Changji 831100,China)

机构地区：[1]新疆昌吉市人民医院检验科,新疆昌吉831100

出　　处：《实用妇科内分泌电子杂志》2022年第5期100-102,共3页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：目的探讨甲胎蛋白(AFP)、血清β-人绒毛膜促性腺激素(β-HCG)、未结合雌三醇(uE_(3))联合检验在孕中期产前出生缺陷筛查中的临床价值。方法选取3575例常规产检的孕中期孕妇,均联合检测AFP、β-HCG、uE_(3),探讨其对产前出生缺陷的筛查价值。结果3575例孕中期孕妇经血清学筛查后高风险孕妇占2.38%,其中89.41%为21-三体综合征高风险,2.35%为18-三体综合征高风险,8.24%为神经管缺陷(NTD)高风险;82例经羊水穿刺检查后5例确诊为出生缺陷儿,均引产于28周内;产前血清AFP、β-HCG、uE_(3)联合检测筛查出生缺陷的敏感性为100%,特异性为97.73%,阳性预测值为4.71%,阴性预测值为100%。结论AFP、β-HCG、uE_(3)联合检验对孕中期产前出生缺陷筛查具有一定临床价值。Objective To investigate the clinical value of AFP,β-human chorionic gonadotropin(β-HCG)and unbound estriol(uE_(3))combined test in the screening of birth defects in the second trimester of pregnancy.Methods 3575 pregnant women in the second trimester of pregnancy were selected for routine prenatal examination β-HCG and uE_(3) in screening prenatal birth defects.Results 3575 second trimester pregnant women were at high risk of NTD after serological screening(2.38%),of which 89.41% were at high risk of 21 trisomy syndrome,2.35% were at high risk of 18 trisomy syndrome,and 8.24% were at high risk of NTD;Birth defects were confirmed in 5 of 82 infants after amniocentesis,all induced within 28 weeks;Prenatal serum AFP、β-HCG、uE_(3) assay had a sensitivity of 100%,a specificity of 97.73%,a positive predictive value of 4.71%,and a negative predictive value of 100% for screening for birth defects.Conclusion AFP、β-HCG、uE_(3) test has some clinical value for second trimester prenatal birth defect screening.

关 键 词：甲胎蛋白 未结合雌三醇 血清β-人绒毛膜促性腺激素 产前出生缺陷 孕中期 

分 类 号：R714.5[医药卫生—妇产科学]